GRI

1.1200.00%
CV

Camilla V. Simpson

Independent Director

Ms. Camilla V. Simpson, M.Sc., is CEO & Director of Zehna Therapeutics, INC. Ms. Simpson is Independent Director of GRI Bio, Inc. from April 2023. She serves as Director at Dyve Biosciences since February 2021. She has been an Independent Director at Spruce Biosciences, Inc. since October 2017. Since April 2021, Ms. Simpson has served as Chief Executive Officer of Zehna Therapeutics, Inc. a biotechnology company and spin-out from the Cleveland Clinic. Ms. Simpson joined the Board of Directors of Dyve Biosciences in December 2020. Ms. Simpson is Managing Member and President of Rare Strategic, LLC since April 2019. Throughout her career, Ms. Simpson has demonstrated a proven track record in delivering novel products for many rare disease indications to global markets in areas of high unmet medical need. Currently, Ms. Simpson is the Managing Member and President of Rare Strategic, LLC, where she provides global regulatory and product development guidance to rare disease and gene therapy companies. Ms. Simpson held numerous executive leadership positions including Senior Vice President, Head of Product Portfolio Development at BioMarin Pharmaceutical Inc. since April 2017 until April 2019. From October 2014 to April 2017, Ms. Simpson was Group Vice President Global Regulatory Affairs at BioMarin and from March 2014 to October 2014, Ms. Simpson was Vice President Regulatory Affairs EU at BioMarin. Ms. Simpson was Vice President Regulatory Affairs Early Development and Business Development at Shire Pharmaceuticals in the United Kingdom. She serves as Member of Scientific Advisory Board of Aristea Therapeutics, Inc. since November 2019. Ms. Simpson holds a Bachelor of. Science from University College Galway, Ireland, a Bachelors of Science (Honors) from Kingston University, United Kingdom and an Masters of Science with distinction from the University of London, UK.

Positions